ESMO 2022 | Use of PARP1-selective and ATR inhibitors to target DDR signalling pathway

Timothy Yap, MBBS, PhD, FRCP, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the use of synthetic lethal strategies in the clinic to challenge DNA damage response. Dr Yap talks about how PARP1-selective and ATR inhibitors may combat tumor growth through blocking of the DDR signalling pathway. He highlights how these drugs could be potentially therapeutic for patients with cancers that possess genomic alterations in DDR pathways. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congree in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.